Semaglutide Rybelsus 14 mg Tablet – Global Dropshipping from India
Newlife Medicare Pvt. Ltd. is a trusted dropshipper from India supplying Semaglutide Rybelsus 14 mg Tablets to international markets including USA, UK, Singapore, @Canada, @Thailand, and @UAE.
Product Details
Rybelsus® (Semaglutide) 14 mg is an oral GLP-1 receptor agonist used in the management of Type 2 Diabetes Mellitus, when prescribed by a qualified healthcare professional.
Key Features
💊 Dosage Strength: 14 mg Tablet
🏭 Quality Standards: WHO-GMP compliant products
📦 Packaging: Export-quality, tamper-proof packing
🚚 Service Type: Dropshipping & bulk supply
🌍 Export Markets: USA, UK, Singapore, Canada, Thailand, UAE
Why Partner with Newlife Medicare Pvt. Ltd.?
Reliable Indian pharmaceutical dropshipper
Competitive pricing for wholesalers and online sellers
Fast processing and secure international shipping
Complete export & regulatory documentation
Consistent stock availability and quality assurance
Therapeutic Use (as prescribed)
Supports effective blood sugar control in adults with Type 2 diabetes
(To be used only under medical supervision.)
📩 Get in touch with Newlife Medicare Pvt. Ltd. for dropshipping, wholesale, and export inquiries for Semaglutide Rybelsus 14 mg Tablets.
Disclaimer: Prescription required. Product details are for informational and export purposes only.
Rs 3, 600 / StripePrice on Request
Product Brochure
strength 14 mg
Form Tablets
Packaging Type Strip
Brand Rybelsus 14 mg
Manufacturer NOVO NORDISK INDIA PVT LTD
Rybelsus Semaglutide 14 mg Tablet is a
medicine used to lower blood sugar levels in adults with type 2 diabetes mellitus. Rybelsus Semaglutide helps prevent serious complications of diabetes like kidney damage and blindness. Rybelsus Semaglutide works by helping the body produce insulin and reducing appetite. It also helps reduce weight in some people.
We export Rybelsus Semaglutide tablets to USA , UK , EUROPE, AUSTARILA, JAPAN , KOREA , CHINA & all over the world
“As Novo Nordisk marks 100 years of commitment and innovation in diabetes care, Rybelsus® remains a pivotal part of our portfolio, making history as the first oral GLP-1 receptor agonist and helping to fuel our mission to improve the lives and health of people living with diabetes.“
